Nona Biosciences, a US-based global biotechnology company, announced on Friday that BeiGene Ltd, a US-based global, science-driven oncology company, has exercised its exclusive option to acquire global development, manufacturing and commercialisation rights for an antibody-drug conjugate (ADC) from DualityBio, a collaborator of Nona Biosciences.

This ADC was manufactured under the partnership contract set up between Nona Biosciences and DualityBio in 2022.

Under the terms of the agreement, Nona Biosciences granted DualityBio exclusive rights to certain monoclonal antibodies targeting specific tumours, enabling the development of first-in-class ADC candidates worldwide.